WO2016077061A3 - Methods and compositions for improved labeling of targeting peptides - Google Patents
Methods and compositions for improved labeling of targeting peptides Download PDFInfo
- Publication number
- WO2016077061A3 WO2016077061A3 PCT/US2015/057350 US2015057350W WO2016077061A3 WO 2016077061 A3 WO2016077061 A3 WO 2016077061A3 US 2015057350 W US2015057350 W US 2015057350W WO 2016077061 A3 WO2016077061 A3 WO 2016077061A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- octreotate
- nota
- methods
- targeting peptides
- compositions
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 230000008685 targeting Effects 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000002372 labelling Methods 0.000 title 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010016076 Octreotide Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 1
- CFODQUSMSYDHBS-UHFFFAOYSA-N octreotate Chemical compound O=C1NC(CC=2C=CC=CC=2)C(=O)NC(CC=2[C]3C=CC=CC3=NC=2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(O)C)C(O)=O)CSSCC1NC(=O)C(N)CC1=CC=CC=C1 CFODQUSMSYDHBS-UHFFFAOYSA-N 0.000 abstract 1
- 229960002700 octreotide Drugs 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/06—Aluminium compounds
- C07F5/069—Aluminium compounds without C-aluminium linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present application discloses compositions and methods of synthesis and use of labeled targeting peptides, such as octreotide, octreotate, or other somatostatin analogs or derivatives. The targeting peptide may be labeled with a therapeutic or diagnostic isotope, such as 61Cu, 62Cu, 64Cu, 67Cu, 18F, 19F, 66Ga, 67Ga, 68Ga, 72Ga, 111In, 177Lu, 44Sc, 47Sc, 86Y, 88Y, 90Y, 45Ti or 89Zr, preferably 18F or 19F. More preferably, the targeting peptide is NOTA-octreotate, NOTA-MPAA-octreotate, pyridine-NOTA-octreotate or triazole-NOTA-octreotate. The labeled targeting peptides may be used for detection, diagnosis, imaging and/or treatment of sst2
+ tumors, such as neuroendocrine tumors.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2965665A CA2965665A1 (en) | 2014-11-12 | 2015-10-26 | Methods and compositions for improved labeling of targeting peptides |
| EP15859382.2A EP3218015A2 (en) | 2014-11-12 | 2015-10-26 | Methods and compositions for improved labeling of targeting peptides |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462078657P | 2014-11-12 | 2014-11-12 | |
| US62/078,657 | 2014-11-12 | ||
| US14/755,712 | 2015-06-30 | ||
| US14/755,712 US20150307524A1 (en) | 2007-01-11 | 2015-06-30 | Methods and Compositions for Improved F-18 Labeling of Proteins, Peptides and Other Molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2016077061A2 WO2016077061A2 (en) | 2016-05-19 |
| WO2016077061A3 true WO2016077061A3 (en) | 2016-08-18 |
Family
ID=55955241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2015/057350 WO2016077061A2 (en) | 2014-11-12 | 2015-10-26 | Methods and compositions for improved labeling of targeting peptides |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3218015A2 (en) |
| CA (1) | CA2965665A1 (en) |
| WO (1) | WO2016077061A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202017600A (en) * | 2018-06-21 | 2020-05-16 | 法商艾普森藥品公司 | Composition containing a somatostatin analogue for radiopharmaceutical use |
| TW202015744A (en) * | 2018-06-21 | 2020-05-01 | 法商艾普森藥品公司 | Composition containing a somatostatin analogue for radiopharmaceutical use |
| CN110339375B (en) * | 2019-05-24 | 2024-02-02 | 广东瑞迪奥科技有限公司 | HER 2-targeted rk polypeptide radiopharmaceuticals and preparation method thereof |
| AU2021262479A1 (en) * | 2020-04-29 | 2022-11-17 | Novartis Ag | Methods for radiolabelling PSMA binding ligands and their kits |
| CN113773365A (en) * | 2021-09-09 | 2021-12-10 | 原子高科股份有限公司 | Somatostatin analogs and uses thereof |
| CN114773433B (en) * | 2022-06-23 | 2022-09-06 | 北京肿瘤医院(北京大学肿瘤医院) | CD25 targeted polypeptide, molecular probe and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140105819A1 (en) * | 2007-01-11 | 2014-04-17 | Immunomedics, Inc. | In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents |
-
2015
- 2015-10-26 CA CA2965665A patent/CA2965665A1/en not_active Abandoned
- 2015-10-26 WO PCT/US2015/057350 patent/WO2016077061A2/en active Application Filing
- 2015-10-26 EP EP15859382.2A patent/EP3218015A2/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140105819A1 (en) * | 2007-01-11 | 2014-04-17 | Immunomedics, Inc. | In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents |
Non-Patent Citations (1)
| Title |
|---|
| LAVERMAN ET AL.: "Optimized labeling of NOTA-conjugated octreotide with F-18", TUMOR BIOL., vol. 33, 2012, pages 427 - 434, XP055356844 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3218015A2 (en) | 2017-09-20 |
| WO2016077061A2 (en) | 2016-05-19 |
| CA2965665A1 (en) | 2016-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016077061A3 (en) | Methods and compositions for improved labeling of targeting peptides | |
| NZ746112A (en) | Cyclic di-nucleotide compounds and methods of use | |
| EP3412304A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| WO2016060996A3 (en) | Interleukin-15 compositions and uses thereof | |
| WO2017042607A3 (en) | Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain | |
| WO2015010078A3 (en) | Substituted 6,5-fused bicyclic heteroaryl compounds | |
| AR100888A1 (en) | DERIVATIVES OF EXENDINA-4 AS SELECTIVE AGONISTS OF THE GLUCAGON RECEIVER | |
| BR112014000466A2 (en) | chimeric and hybrid factor viii polypeptides, methods of using them | |
| NZ708528A (en) | Anti-ceacam5 antibodies and uses thereof | |
| WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
| GB201019331D0 (en) | Methods for the diagnosis and treatment of cancer based on AVL9 | |
| WO2016014342A3 (en) | Ang-(1-7) derviative oligopeptides and methods for using and producing the same | |
| JP2017530130A5 (en) | ||
| MX2011007963A (en) | Neil3 peptides and vaccines including the same. | |
| WO2018069831A3 (en) | Ligands of the fsh hormone receptor in the diagnosis and treatment of tumors | |
| MX2021010595A (en) | Pharmaceutical composition, preparation and uses thereof. | |
| AU2019284019A1 (en) | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions | |
| EA201790223A1 (en) | WATER PREPARATION CONTAINING PARACETAMOL AND IBUPROFEN | |
| NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
| EP3263123A3 (en) | Shk-based pharmaceutical compositions and methods of manufacturing and using the same | |
| WO2016015055A8 (en) | Colon cleansing compositions | |
| PH12015502072B1 (en) | Nutritional compositions containing a peptide component and uses thereof | |
| EA201690966A1 (en) | NEW CONNECTION FOR THE TREATMENT OF HEAVY HYPOGLYCEMIA | |
| WO2016130518A3 (en) | Methods and compositions for treating muscle disease and disorders | |
| WO2016057660A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15859382 Country of ref document: EP Kind code of ref document: A2 |
|
| ENP | Entry into the national phase |
Ref document number: 2965665 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REEP | Request for entry into the european phase |
Ref document number: 2015859382 Country of ref document: EP |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15859382 Country of ref document: EP Kind code of ref document: A2 |